Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial

Table 1 Patient demographics

		N = 50
Sex	Male	32 (64%)
	Female	18 (36%)
Age	mean ± SD	63.74 ± 11.2
	Median (p25-p75)	66.7 (58-71)
	Range	32-85
ECOG-PS	0	16 (32%)
	1	25 (50%)
	2	9 (18%)
Comorbidities: Charlson Index	No	39 (78%)
	Yes	11 (22%)
Weight loss > 5% of body weight1	No	23 (46%)
	Yes	21 (42%)
	N/A	6 (12%)
1st line palliative chemotherapy	mFOLFIRINOX	14 (28%)
	Gemcitabine + Nab/Paclitaxel	25 (50%)
	Gemcitabine	8 (16%)
	Capecitabine	3 (6%)
Stage	4	50 (100%)
Site of distant metastases	Only liver	18 (36%)
	Only peritoneal carcinomatosis	6 (12%)
	Only lung	5 (10%)
	> 1 location	21 (42%)

¹Weight loss > 5% in the 3 mo prior to diagnosis.

ECOG-PS: Eastern Cooperative Group Performance Status; N/A: Not applicable; mFOLFIRINOX: Modified fluorouracil, leucovorin, irinotecan and oxaliplatin.